Table I.

Proportion of participants with asthma and severe asthma eligible for mAb therapy

mAb eligibility		Weighted % (95% CI)*
	Overall	≤18 y	>18 y
Eligible for at least 1 biologic
All asthma (n = 3039)	2.8 (1.9–3.7)	2.6 (1.4–3.9)	2.8 (1.8–3.8)
Severe asthma (n = 104)	84.7 (73.0–96.4)	89.7 (74.1–97.9)	83.9 (70.4–97.4)
Eligible for all the 5 biologics
All asthma	0.2 (0.0–0.5)	0	0.2 (0.0–0.6)
Severe asthma	6.4 (3.1–15.9)	0	7.4 (3.5–18.3)
Anti-IL-5 therapy
Mepolizumab
All asthma	2.2 (1.5–3.1)	2.5 (1.5–3.1)	2.1 (1.5–3.1)
Severe asthma	72.1 (59.6–81.8)	88.5 (62.9–97.2)	66.9 (53.3–78.2)
Benralizumab
All asthma	1.3 (0.8–2.1)	1.9 (1.0–3.5)	1.1 (0.6–1.9)
Severe asthma	40.2 (26.7–55.4)	62.8 (42.8–82.6)	32.3 (18.7–49.7)
Reslizumab
All asthma	0.5 (0.3–1.0)	0	0.7 (0.4–1.4)
Severe asthma	14.8 (7.1–28.4)	0	19.5 (9.4–36.0)
Anti-IL-4/13 receptor alpha
Dupilumab
All asthma	2.4 (1.7–3.3)	1.9 (1.0–3.5)	2.5 (1.8–3.5)
Severe asthma	73.4 (63.4–81.4)	67.8 (46.2–83.7)	75.1 (64.0–83.7)
Anti-IgE†
Omalizumab
All asthma	1.4 (0.6–2.1)	1.3 (0.2–2.4)	1.4 (0.5–2.2)
Severe asthma	41.4 (22.8–60.1)	42.5 (10.1–75.0)	41.3 (19.5–63.2)
Original data
All asthma	1.6 (0.7–3.8)	QNS	QNS
Severe asthma	58.5 (30.7–81.8)	QNS	QNS

QNS, Insufficient sample.

^*NHANES sample weights based on the complex sampling survey design were used in constructing estimates.

^†Original data are from the period 2005–2006. IgE and sensitivity to perennial allergens for the period 2007–2012 imputed. Only 8 participants were eligible for omalizumab from 2005 to 2006, and only 20 had “severe” asthma.